Objective To investigate the expressions of C-erbB-2, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer tissues and to explore their relationship with patients-age, tumor size, lymph node metastasis, histopathological type and the stage of cancer.
Methods The expressions of C-erbB-2, ER and PR in 83 cases of breast cancer tissues were detected by immunohistochemistry and the clinical significance was statistically analyzed.
Results The positive expression rate of C-erbB-2, ER and PR in 83 cases of breast cancer tissues were 78.3%, 56.6% and 55.4%, respectively. The expressions of C-erbB-2, ER and PR were not correlated to patients’ age, tumor size, histopathological type and the stage of cancer (P gt;0.05). While the expression of C-erbB-2 rather than ER and PR was correlated to lymph node metastasis (P<0.05) and the correlation was positive (r=0.387, P<0.05).
Conclusion The positive expression of C-erbB-2 is one of lymph node metastasis factors for breast cancer patients. Combined detection of ER and PR expression may be helpful to clinical treatment and predict prognosis for breast cancer patients.
Citation:
QIAN Jinfeng,CAI Dewei,XIE Huijun.. Correlation of Expressions of C-erbB-2, ER and PR to Clinicopathologic Factors in Primary Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(7): 518-521. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
1. |
陈红秋, 粟连秀, 杨达平, 等. ER、PR、CerbB2及p53在乳腺癌中的表达及意义 [J]. 广西医学, 2008; 30(3): 343344.
|
2. |
范伟, 杨金巧, 伍晓汀, 等. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [J]. 中国普外基础与临床杂志, 2004; 11(1): 1416.
|
3. |
赵丽华, 林竞, 石柏, 等. 乳腺癌ER、PR的表达与临床病理意义 [J]. 基层医学论坛, 2006; 10(9): 804805.
|
4. |
程虹, 戴林, 郭双平译. Tavassoli FA, Devilee P主编. 乳腺及女性生殖器官肿瘤病理学和遗传学 [M]. 第1版. 北京: 人民卫生出版社, 2006: 23.
|
5. |
Ledingham IM, Mackey C. International union against cancer TNM classification of malignant tumors [A]. In: Ledingham IM, Mackey C. eds. Surgical Pathology [M]. 4th ed. Edinburgh London Melbourne and New York: Churchill Liringstone, 1998: 8591.
|
6. |
Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays [J]. Am J Clin Pathol, 2001; 115(1): 4449.
|
7. |
Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogenregulated protein, cathepsin D, in breast cancer. An immunohistochemical study [J]. Cancer,1990; 65(2): 265269.
|
8. |
Learn PA, Yeh IT, McNutt M, et al. HER2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma [J]. Cancer, 2005; 103(11): 22522260.
|
9. |
董永红, 吕云福, 匡玉庭, 等. 乳腺癌CerbB2 DNA的预后价值 [J]. 第四军医大学学报, 2002; 23(21): 19331936.
|
10. |
罗静, 郑金锋, 刘莹, 等主编. 免疫组织化学与肿瘤病理诊断 [M]. 第2版. 北京: 人民军医出版社, 2004: 138142.
|
11. |
刘静贤, 高琨, 刘毅强, 等. 乳腺癌CerbB2、p53、ER和PR表达及意义 [J]. 中国肿瘤临床与康复, 2003; 10(1): 1516.
|
12. |
杨丽芳, 宋三泰, 李晓兵, 等. 284例原发乳腺癌cerbB2蛋白的表达及其与预后的关系 [J]. 中华肿瘤杂志, 2006; 28(4): 294297.
|
13. |
张英, 刘永源, 黄应桂, 等. 青年和绝经后女性乳腺癌cerbB2、p53、ER和PR受体表达及意义 [J]. 肿瘤防治研究, 2004; 31(2): 7980.
|
14. |
Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptorpositive primary breast cancer [J]. J Natl Cancer Inst, 2003; 95(2): 142153.
|
15. |
姚卫康, 包建荣, 吴德明, 等. 乳腺癌CerbB2的表达及其与ER、PR的相关性研究 [J]. 中国医师进修杂志(综合版), 2007; 30 (6): 79.
|
16. |
Borg A, Tandon AK, Sigurdsson H, et al. HER2/neu amplification predicts poor survival in nodepositive breast cancer [J]. Cancer Res, 1990; 50(14): 43324337.
|
17. |
刘艳, 张瑾, 郝晓甍, 等. 乳腺癌Her2基因过表达与年龄临床病理状态的相关性研究 [J]. 中国肿瘤临床, 2007; 34 (24): 13921395.
|
18. |
胡应光. 乳腺癌ER、PR、p53、cerbB2表达的临床意义 [J]. 中国基层医药, 2007; 14 (6): 941942.
|
19. |
姚卫康, 包建荣, 吴德明, 等. cerbB2、ER、PR在乳腺癌中的表达及其临床意义 [J]. 苏州大学学报(医学版), 2007; 27(4): 569571.
|
20. |
杨金巧. 乳腺癌的内分泌治疗及研究进展 [J]. 中国普外基础与临床杂志, 2004; 11(1): 1213.
|
21. |
Ravdin PM, Chamness GC. The cerbB2 protooncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review [J]. Gene, 1995; 159(1): 19-24.
|
- 1. 陈红秋, 粟连秀, 杨达平, 等. ER、PR、CerbB2及p53在乳腺癌中的表达及意义 [J]. 广西医学, 2008; 30(3): 343344.
- 2. 范伟, 杨金巧, 伍晓汀, 等. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [J]. 中国普外基础与临床杂志, 2004; 11(1): 1416.
- 3. 赵丽华, 林竞, 石柏, 等. 乳腺癌ER、PR的表达与临床病理意义 [J]. 基层医学论坛, 2006; 10(9): 804805.
- 4. 程虹, 戴林, 郭双平译. Tavassoli FA, Devilee P主编. 乳腺及女性生殖器官肿瘤病理学和遗传学 [M]. 第1版. 北京: 人民卫生出版社, 2006: 23.
- 5. Ledingham IM, Mackey C. International union against cancer TNM classification of malignant tumors [A]. In: Ledingham IM, Mackey C. eds. Surgical Pathology [M]. 4th ed. Edinburgh London Melbourne and New York: Churchill Liringstone, 1998: 8591.
- 6. Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays [J]. Am J Clin Pathol, 2001; 115(1): 4449.
- 7. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogenregulated protein, cathepsin D, in breast cancer. An immunohistochemical study [J]. Cancer,1990; 65(2): 265269.
- 8. Learn PA, Yeh IT, McNutt M, et al. HER2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma [J]. Cancer, 2005; 103(11): 22522260.
- 9. 董永红, 吕云福, 匡玉庭, 等. 乳腺癌CerbB2 DNA的预后价值 [J]. 第四军医大学学报, 2002; 23(21): 19331936.
- 10. 罗静, 郑金锋, 刘莹, 等主编. 免疫组织化学与肿瘤病理诊断 [M]. 第2版. 北京: 人民军医出版社, 2004: 138142.
- 11. 刘静贤, 高琨, 刘毅强, 等. 乳腺癌CerbB2、p53、ER和PR表达及意义 [J]. 中国肿瘤临床与康复, 2003; 10(1): 1516.
- 12. 杨丽芳, 宋三泰, 李晓兵, 等. 284例原发乳腺癌cerbB2蛋白的表达及其与预后的关系 [J]. 中华肿瘤杂志, 2006; 28(4): 294297.
- 13. 张英, 刘永源, 黄应桂, 等. 青年和绝经后女性乳腺癌cerbB2、p53、ER和PR受体表达及意义 [J]. 肿瘤防治研究, 2004; 31(2): 7980.
- 14. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptorpositive primary breast cancer [J]. J Natl Cancer Inst, 2003; 95(2): 142153.
- 15. 姚卫康, 包建荣, 吴德明, 等. 乳腺癌CerbB2的表达及其与ER、PR的相关性研究 [J]. 中国医师进修杂志(综合版), 2007; 30 (6): 79.
- 16. Borg A, Tandon AK, Sigurdsson H, et al. HER2/neu amplification predicts poor survival in nodepositive breast cancer [J]. Cancer Res, 1990; 50(14): 43324337.
- 17. 刘艳, 张瑾, 郝晓甍, 等. 乳腺癌Her2基因过表达与年龄临床病理状态的相关性研究 [J]. 中国肿瘤临床, 2007; 34 (24): 13921395.
- 18. 胡应光. 乳腺癌ER、PR、p53、cerbB2表达的临床意义 [J]. 中国基层医药, 2007; 14 (6): 941942.
- 19. 姚卫康, 包建荣, 吴德明, 等. cerbB2、ER、PR在乳腺癌中的表达及其临床意义 [J]. 苏州大学学报(医学版), 2007; 27(4): 569571.
- 20. 杨金巧. 乳腺癌的内分泌治疗及研究进展 [J]. 中国普外基础与临床杂志, 2004; 11(1): 1213.
- 21. Ravdin PM, Chamness GC. The cerbB2 protooncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review [J]. Gene, 1995; 159(1): 19-24.